Slowdowns in the transport and delivery of nutrients, proteins and signaling molecules within nerve cells may contribute to the development of the neurodegenerative disorder ALS, according to researchers at the University of Illinois at Chicago College of Medicine. The researchers showed how a...
For the first time, hopes are raised that the devastating and fatal nerve-cell-wasting disease amyotrophic lateral sclerosis (ALS) may be treatable, following a recently published review of 11 independent animal studies of the disease. The accumulated evidence shows it may be possible to...
Research led by Dr. Udai Pandey, Assistant Professor of Genetics at LSU Health Sciences Center New Orleans, has found that the ability of a protein made by a gene called FUS to bind to RNA is essential to the development of Amyotrophic Lateral Sclerosis (ALS). This discovery identifies a...
Researchers at Mayo Clinic in Florida have uncovered a toxic cellular process by which a protein that maintains the health of neurons becomes deficient and can lead to dementia. The findings shed new light on the link between culprits implicated in two devastating neurological diseases...
A Purdue University biochemist has determined the function of a gene that when mutated leads to a genetic variation of amyotrophic lateral sclerosis, or Lou Gehrig's disease. James Clemens, an assistant professor of biochemistry, found that a gene called VAPB is responsible for transporting...
With the help of baker's yeast, a tiny one-celled organism, scientists in the US say they have found a "chink in the armor" of the currently incurable disease Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. They suggest their finding offers a new target for therapies...
Professional football players are much more likely to die from Alzheimer's disease, ALS (Lou Gerhig's disease) and other conditions cause by brain-cell damage, researchers from the National Institute for Occupational Safety and Health in Cincinnati wrote in the journal Neurology. The scientists...
A team of scientists, including faculty at the University of Massachusetts Medical School (UMMS), have discovered a gene that influences survival time in amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). The study, published in Nature Medicine, describes how the loss of...
Neuralstem, Inc. (NYSE Amex: CUR) announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cell. "Lumbar Intraspinal Injection of Neural Stem...
The underlying disease process of amyotrophic lateral sclerosis (ALS and Lou Gehrig's disease), a fatal neurodegenerative disease that paralyzes its victims, has long eluded scientists and prevented development of effective therapies. Scientists weren't even sure all its forms actually converged...
The Fukushima Update #30 has been translated into German. So if German is your preferred language, you can go read it here. Thanks Frank Braun for the translation.
Read the comments on this post...
Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's...
Hospital for Special Care announced the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of...
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20 percent of all familial ALS cases are...
Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human...
Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human...